Calton & Associates’s Acceleron Pharma XLRN Stock Holding History

Calton & Associates’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,151	Closed	-$370K	–	417
2021 Q3	$370K	Sell	2,151 -17	-0.8%	-$2.22K	0.08%	249
2021 Q2	$272K	Sell	2,168 -71	-3%	-$8.96K	0.05%	312
2021 Q1	$304K	Buy	2,239 +189	+9%	+$24.4K	0.06%	283
2020 Q4	$262K	Sell	2,050 -81	-4%	-$9.5K	0.05%	291
2020 Q3	$240K	Buy	+2,131	New	+$212K	0.05%	280

Calton & Associates's XLRN Position: Q4 2021 in Review

Calton & Associates sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 2,151 shares — an estimated $370K sold.

Calton & Associates first reported a position in XLRN in Q3 2020 and held it in 5 quarters. The position peaked at $370K in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Calton & Associates reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Calton & Associates sold 2,151 Acceleron Pharma shares in Q4 2021, an estimated $370K.
Calton & Associates first reported a position in Acceleron Pharma in Q3 2020 and held it in 5 quarters.
Calton & Associates's Acceleron Pharma position peaked at $370K in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Calton & Associates's 13F filing for Q4 2021, filed 13 Jan 2022.